Stocktoria
Adaptimmune Therapeutics PLC ADAPY
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-05-06
Adaptimmune Therapeutics PLC financials (annual, from 10-K)
Bars are annual figures from 2015 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M | $1.1M | $59.5M | $37.8M | $14.2M | $9.9M |
| R&D expense | $149.1M | $126.5M | $127.7M | $111.1M | $91.6M | $97.5M | $98.3M | $87.4M | $63.8M | $24.1M |
| SG&A expense | $87.3M | $73.5M | $63.4M | — | — | — | — | — | — | — |
| Operating income | -$68.8M | -$139.7M | -$164.0M | -$162.2M | -$133.4M | -$139.8M | -$82.4M | -$80.7M | -$72.8M | -$24.6M |
| Income tax | $3.6M | $1.3M | $2.5M | $791,000 | $162,000 | $242,000 | $497,000 | $451,000 | $892,000 | $244,000 |
| Net income | -$70.8M | -$113.9M | -$165.5M | -$158.1M | -$130.1M | -$137.2M | -$95.5M | -$70.1M | -$71.6M | -$22.1M |
| EPS (diluted) | $-0.05 | $-0.09 | $-0.17 | $-0.17 | $-0.15 | $-0.22 | — | — | — | — |
| Operating cash flow | -$73.2M | -$140.9M | -$141.8M | $10.7M | -$53.6M | -$112.5M | -$104.4M | -$54.3M | -$48.2M | -$29.7M |
| Free cash flow | -$74.1M | -$145.6M | -$171.3M | $2.2M | -$55.9M | -$114.1M | -$108.3M | -$79.0M | -$59.7M | -$34.7M |
| Cash & equivalents | $91.1M | $144.0M | $108.0M | $149.9M | $56.9M | $50.4M | $68.4M | $84.0M | $158.8M | $229.0M |
| Inventory | $7.3M | — | — | — | — | — | — | — | — | — |
| Total assets | $246.0M | $282.6M | $328.9M | $469.5M | $451.1M | $181.5M | $276.7M | $281.1M | $234.5M | $300.7M |
| Total liabilities | $234.1M | $243.1M | $247.0M | $263.6M | $109.9M | $57.9M | $29.9M | $78.2M | $68.4M | $41.6M |
| Shareholders' equity | $11.8M | $39.5M | $81.9M | $206.0M | $341.2M | $123.6M | $246.9M | $203.0M | $166.1M | $259.0M |
Growth · year-over-year · Revenue CAGR 37.9%
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +195.3% | +122.0% | +341.5% | +55.4% | +252.8% | -98.1% | +57.3% | +166.5% | +43.8% | — |
| Free cash flow growth | — | — | -8047.3% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001621227 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.